 |
answer text |
<p>On 10 August 2022, the Department referred Evusheld to the National Institute for
Health and Care Excellence (NICE) to evaluate its clinical and cost effectiveness
for preventing COVID-19. From 29 July to 12 August 2022, NICE consulted with provisional
stakeholders on the suggested remit, draft scope and provisional stakeholder list
of consultees and commentators.</p><p>NICE has begun its evaluation and currently
expects to publish draft guidance in April 2023 with final guidance in May 2023. In
discussion with the manufacturer AstraZeneca, NICE is expediting the appraisal process
by bringing forward the deadline for the company’s evidence submission in order to
issue guidance to the National Health Service as soon as possible.</p>
|
 |
